AXLA - Axcella Health Inc Stock Price, Fair Value and News

$0.40

Market Closed

AXLA Stock Valuation Analysis

Valuation

Max Portfolio %

AXLA Price Action

AXLA RSI Chart

AXLA Stock Valuation Analysis

Valuation

Max Portfolio %

AXLA Valuation

AXLA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AXLA Fundamentals

AXLA Revenue

AXLA Earnings

AXLA Profitability

AXLA Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q4
2023	0	0	0
2022	260.7K	382.3K	504.0K
2021	250.3K	194.7K	139.0K
2020	1.3M	808.7K	306.0K
2019	1.2M	0	1.8M
2018	0	0	547.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Axcella Health Inc

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

CEO	Mr. William R. Hinshaw Jr.
WEBSITE	axcellahealth.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	11